Search research articles
Contact Us
Filters
Showing results (71-80 of 83) with videos related to
Page
of 9
Sort By:
Ebiomedicine
|
September 27, 2025
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial
Lisanne A H Bevers, Gabriela Toledo, Muzamil Kisekka, et al.
The Lancet. Child & Adolescent Health
|
August 10, 2023
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
Anna Turkova, Ellen White, Adeodata R Kekitiinwa, et al.
Plos Medicine
|
January 31, 2018
Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study
, Ali Judd, Elizabeth Chappell, et al.
The European Respiratory Journal
|
December 18, 2025
Efficacy of isoniazid in pediatric tuberculosis: an individual participant data meta-analysis
Agathe Béranger, Belén P Solans, Ryo Miyakawa, et al.
Contemporary Clinical Trials
|
April 18, 2024
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years
Anna Turkova, Man K Chan, Cissy Kityo, et al.
The New England Journal of Medicine
|
March 9, 2022
Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children
Anna Turkova, Genevieve H Wills, Eric Wobudeya, et al.
BMJ Open
|
April 3, 2025
Effectiveness and safety of shortened intensive treatment for children with tuberculous meningitis (SURE): a protocol for a phase 3 randomised controlled trial evaluating 6 months of antituberculosis therapy and 8 weeks of aspirin in Asian and African children with tuberculous meningitis
Julie Huynh, Chishala Chabala, Suvasini Sharma, et al.
Journal of the International AIDS Society
|
September 28, 2023
Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trial
Linda Namutebi Barlow-Mosha, Grace Miriam Ahimbisibwe, Elizabeth Chappell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 11, 2025
Viral suppression, viral failure and safety outcomes in children and adolescents living with HIV on dolutegravir in Europe and Thailand
Karen Scott, John O'Rourke, Charlotte Jackson, et al.
The New England Journal of Medicine
|
May 14, 2025
Second-Line Antiretroviral Therapy for Children Living with HIV in Africa
Victor Musiime, Mutsa Bwakura-Dangarembizi, Alexander J Szubert, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 83) with videos related to
Sort By:
Page
of 9
Ebiomedicine
|
September 27, 2025
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial
Lisanne A H Bevers, Gabriela Toledo, Muzamil Kisekka, et al.
The Lancet. Child & Adolescent Health
|
August 10, 2023
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
Anna Turkova, Ellen White, Adeodata R Kekitiinwa, et al.
Plos Medicine
|
January 31, 2018
Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study
, Ali Judd, Elizabeth Chappell, et al.
The European Respiratory Journal
|
December 18, 2025
Efficacy of isoniazid in pediatric tuberculosis: an individual participant data meta-analysis
Agathe Béranger, Belén P Solans, Ryo Miyakawa, et al.
Contemporary Clinical Trials
|
April 18, 2024
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years
Anna Turkova, Man K Chan, Cissy Kityo, et al.
The New England Journal of Medicine
|
March 9, 2022
Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children
Anna Turkova, Genevieve H Wills, Eric Wobudeya, et al.
BMJ Open
|
April 3, 2025
Effectiveness and safety of shortened intensive treatment for children with tuberculous meningitis (SURE): a protocol for a phase 3 randomised controlled trial evaluating 6 months of antituberculosis therapy and 8 weeks of aspirin in Asian and African children with tuberculous meningitis
Julie Huynh, Chishala Chabala, Suvasini Sharma, et al.
Journal of the International AIDS Society
|
September 28, 2023
Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trial
Linda Namutebi Barlow-Mosha, Grace Miriam Ahimbisibwe, Elizabeth Chappell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 11, 2025
Viral suppression, viral failure and safety outcomes in children and adolescents living with HIV on dolutegravir in Europe and Thailand
Karen Scott, John O'Rourke, Charlotte Jackson, et al.
The New England Journal of Medicine
|
May 14, 2025
Second-Line Antiretroviral Therapy for Children Living with HIV in Africa
Victor Musiime, Mutsa Bwakura-Dangarembizi, Alexander J Szubert, et al.
Page
of 9